Completed PHASE3 INTERVENTIONAL NCT00293124

Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors

An Open-label Trial of Glivec in Patients With Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors Expressing C-kit.

Sponsor: Central European Cooperative Oncology Group

Conditions Gastrointestinal Stromal Tumors

Interventions Glivec

Updated 6 times since 2017 Last updated: Aug 11, 2015 Started: Mar 31, 2004 Primary completion: Jul 31, 2006 Completion: Jul 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Gastrointestinal Stromal Tumors and is currently completed. Central European Cooperative Oncology Group leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Central European Cooperative Oncology Group

Data source: Central European Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Belgrade, Serbia , Bratislava, Slovakia , Bucharest, Romania , Cluj-Napoca, Romania , Craiova, Romania , Ljubljana, Slovenia , Prague, Czechia , Sarajevo, Bosnia and Herzegovina , Sofia, Bulgaria , Split, Croatia and 3 more locations